Teva Names Former Sandoz CEO Francis To Replace Schultz Within Weeks
Richard Francis Will Take Lead At Israeli Generics Giant From The Start Of 2023
In just under six weeks Teva will have a new president and CEO, after former Sandoz chief Richard Francis was announced as Kåre Schultz’s replacement from the start of 2023.
You may also be interested in...
With Teva clearing up early who will replace outgoing president and CEO Kåre Schultz, Generics Bulletin looks at five issues that await his replacement, the former Sandoz head Richard Francis.
Teva has announced a finalized nationwide settlement over its long-running opioids litigation, signalling the start of a sign-on process for individual states, subdivisions and special districts. The company remains optimistic of a high participation rate.
Teva’s final quarterly earnings call of the year was indicative of its continued need to push valuable pipeline projects in the US to commercialization, as it once again lowered its full-year 2022 revenue guidance.